7689-63-6

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-1,5-naphthyridine is used as a key intermediate for the synthesis of various pharmaceutical compounds. Its ability to undergo nucleophilic substitution and cross-coupling reactions allows for the creation of a wide range of important compounds with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 4-chloro-1,5-naphthyridine serves as a valuable building block for the development of new agrochemicals. Its versatility in organic synthesis enables the production of compounds with potential applications in crop protection and pest control.
Used in Organic Synthesis:
4-Chloro-1,5-naphthyridine is utilized as a versatile intermediate in organic synthesis. Its reactivity in various chemical reactions, such as nucleophilic substitution and cross-coupling reactions, makes it a valuable component in the synthesis of a broad spectrum of organic compounds for different applications.

InChI:InChI=1/C8H5ClN2/c9-6-3-5-10-7-2-1-4-11-8(6)7/h1-5H

Upstream product

• 16795-72-5 4-oxo-1,4-dihydro-1,5-naphthyridine 
• 27305-48-2 1,5-naphthyridine N-⁽¹⁾-oxide 
• 254-79-5 1,5-naphthyridine 
• 25063-68-7 2,2-dimethyl-5-[(pyridin-3-ylamino)methylidene]-1,3-dioxane-4,6-dione 
• 462-08-8 pyridin-3-ylamine 
• 1018812-89-9 1,5-naphthyridin-5-oxide 4-ol 
• 952059-56-2 2,2-dimethyl-5-[[(1-oxidopyridin-3-yl)amino]methylidene]-1,3-dioxane-4,6-dione 
• 5423-54-1 4-hydroxy-1,5-naphthyridine 

Downstream Products

• 5423-93-8 N¹,N¹-diethyl-N⁴-1,5-naphthyridin-4-ylpentane-1,4-diamine 
• 27392-68-3 4-amino-1,5-naphthyridine 
• 952059-67-5 2-[2-methoxy-4-(1,5-naphthyridin-4-yloxy)phenyl]acetic acid 
• 1201842-52-5 N-(2-chloro-5-(1,5-naphthyridin-4-yl)-3-pyridinyl)-4-fluorobenzenesulfonamide 
• 1394084-03-7 N-[1,5]Naphthyridin-4-yl-benzenesulfonamide 
• 79425-97-1 N-[1,5]Naphthyridin-4-yl-N'-[1-(4-nitro-phenyl)-meth-(Z)-ylidene]-hydrazine 
• 79426-11-2 4-benzylsulfonyl-1,5-naphthyridine 1-oxide 
• 79426-10-1 4-benzylthio-1,5-naphthyridine 1-oxide 
• 79425-95-9 4-Phenylmethanesulfonyl-[1,5]naphthyridine 
• 79425-93-7 4-Benzylsulfanyl-[1,5]naphthyridine 
• 79426-14-5 1,5-naphthyridine-4-carboxylic acid 
• 79425-89-1 4-mercapto-1,5-naphthyridine 
• 152563-03-6 4-iodo-1,5-naphthyridine 
• 79425-96-0 4-hydrazino-1,5-naphthyridine 

Relevant academic research and scientific papers

Synthesis and complexation behavior of indenyl and cyclopentadienyl ligands functionalized with a naphthyridine unit

Lithium indenide (Li-Ind) or cyclopentadienide (Li-Cp) derivatives react as nucleophiles with 8-(methylsulfinyl)- 1,5-naphthyridine (Naph), leading to donor-functionalized ligands IndNaph or CpNaph, respectively. The new ligands comprise two N-donor atoms, which, for geometric reasons, cannot bind to the same metal atom. In complexes, where the metal atom is bound by the Cp or Ind moiety, the N5-donor atom is located in a distal position. The coordination behavior to Rh or Zr metal centers has been investigated. The Cp-based ligands show the expected chelating coordination mode with ν5-Cp and N coordination, whereas the indenyl units act as dihapto, trihapto, or pentahapto ligands. The dinuclear Rh(I) complex 12 shows a rare coordination geometry with two ν3 ligands bridging a Rh 2(CO)3 fragment.

INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS

Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.

Selective Halogenation of Pyridines Using Designed Phosphine Reagents

Halopyridines are key building blocks for synthesizing pharmaceuticals, agrochemicals, and ligands for metal complexes, but strategies to selectively halogenate pyridine C-H precursors are lacking. We designed a set of heterocyclic phosphines that are installed at the 4-position of pyridines as phosphonium salts and then displaced with halide nucleophiles. A broad range of unactivated pyridines can be halogenated, and the method is viable for late-stage halogenation of complex pharmaceuticals. Computational studies indicate that C-halogen bond formation occurs via an SNAr pathway, and phosphine elimination is the rate-determining step. Steric interactions during C-P bond cleavage account for differences in reactivity between 2- and 3-substituted pyridines.

Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action

Ebola virus (EBOV) causes a deadly hemorrhagic fever in humans and non-human primates. There is currently no FDA-approved vaccine or medication to counter this disease. Here, we report on the design, synthesis and anti-viral activities of two classes of compounds which show high potency against EBOV in both in vitro cell culture assays and in vivo mouse models Ebola viral disease. These compounds incorporate the structural features of cationic amphiphilic drugs (CAD), i.e they possess both a hydrophobic domain and a hydrophilic domain consisting of an ionizable amine functional group. These structural features enable easily diffusion into cells but once inside an acidic compartment their amine groups became protonated, ionized and remain trapped inside the acidic compartments such as late endosomes and lysosomes. These compounds, by virtue of their lysomotrophic functions, blocked EBOV entry. However, unlike other drugs containing a CAD moiety including chloroquine and amodiaquine, compounds reported in this study display faster kinetics of accumulation in the lysosomes, robust expansion of late endosome/lysosomes, relatively more potent suppression of lysosome fusion with other vesicular compartments and inhibition of cathepsins activities, all of which play a vital role in anti-EBOV activity. Furthermore, the diazachrysene 2 (ZSML08) that showed most potent activity against EBOV in in vitro cell culture assays also showed significant survival benefit with 100% protection in mouse models of Ebola virus disease, at a low dose of 10 mg/kg/day. Lastly, toxicity studies in vivo using zebrafish models suggest no developmental defects or toxicity associated with these compounds. Overall, these studies describe two new pharmacophores that by virtue of being potent lysosomotrophs, display potent anti-EBOV activities both in vitro and in vivo animal models of EBOV disease.

A fluorescent material, preparation method and application

The invention discloses a kind of fluorescent material, preparation method and application, wherein the fluorescent material of the molecular structure of the general formula as follows: R1 - R6 are each independently selected from H atom, deuterium atoms, to the electronic group or pulling in the electronic group a; and R1 - R6 at least one electron-donating groups, at least one of the is dragging the electronic group. The present invention provides fluorescent material, with twisted of - A D (Donor) (Acceptor) structure, at the same time with a heat-activated delay fluorescent and aggregation induced characteristic, not only can realize 100% internal quantum efficiency, but also can reduce the aggregation caused by the luminescence quenching process. These material is used as the doping and-layer films of the organic electroluminescent device in the light-emitting layer of the light-emitting object, its efficiency can be comparable with the phosphorescence, and avoid the problems of the prior phosphorescent material usually to use heavy metal is the iridium, platinum and the problem of expensive heavy metal, the cost is reduced.

Naphthyridine-based emitters simultaneously exhibiting thermally activated delayed fluorescence and aggregation-induced emission for highly efficient non-doped fluorescent OLEDs

Luminescent materials simultaneously exhibiting superior luminescence efficiency, thermally activated delayed fluorescence (TADF) and aggregation-induced emission (AIE) properties in the solid state are eagerly required for highly efficient non-doped organic light-emitting diodes (OLEDs). Herein, two new emitters, namely ND-AC and CND-AC, featuring a naphthyridine or cyano-naphthyridine segment as the electron acceptor and an acridine unit as the electron donor were designed, synthesized and investigated. The nearly orthogonal molecular configuration of the target emitters not only endows them with small energy differences between singlet and triplet states for ensuring TADF character but also affords a remarkable AIE feature. Due to the high photoluminescence quantum yields, and excellent TADF and AIE characteristics, the doped and non-doped OLEDs based on ND-AC exhibit outstanding performances with maximum external quantum efficiencies of 16.8% and 12.0%, respectively. These results demonstrate that the naphthyridine-based emitters have a promising application in OLEDs.

Fluorescent material as well as preparation method and application thereof

The invention discloses a fluorescent material as well as a preparation method and application thereof. The structural general formula of the fluorescent material is formula (shown in the description), wherein R1-R10 are respectively independently selecte

TOLL-LIKE RECEPTOR 8 (TLR8)-SPECIFIC ANTAGONISTS AND METHODS OF MAKING AND USES THEREOF

Toll-like receptor 8 (TLR8)-specific inhibitors and methods of using the same in individuals having an autoimmune disease or an inflammatory disorder.

HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME

The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to the CXCR4 pathway.

Discovery of an Inhibitor of the Proteasome Subunit Rpn11

The proteasome plays a crucial role in degradation of normal proteins that happen to be constitutively or inducibly unstable, and in this capacity it plays a regulatory role. Additionally, it degrades abnormal/damaged/mutant/misfolded proteins, which serves a quality-control function. Inhibitors of the proteasome have been validated in the treatment of multiple myeloma, with several FDA-approved therapeutics. Rpn11 is a Zn2+-dependent metalloisopeptidase that hydrolyzes ubiquitin from tagged proteins that are trafficked to the proteasome for degradation. A fragment-based drug discovery (FBDD) approach was utilized to identify fragments with activity against Rpn11. Screening of a library of metal-binding pharmacophores (MBPs) revealed that 8-thioquinoline (8TQ, IC50 value ～2.5 μM) displayed strong inhibition of Rpn11. Further synthetic elaboration of 8TQ yielded a small molecule compound (35, IC50 value ～400 nM) that is a potent and selective inhibitor of Rpn11 that blocks proliferation of tumor cells in culture.